All In Biotech

Drug Trial Radar · NCT04669600

A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)

A Multicenter, Phase 2a, Open-label, Non-randomized Study Evaluating the Efficacy, Safety, and Tolerability of BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)

Last checked: Nov 19, 2026Latest source record: Sep 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

12

Actual

Start

Feb 4, 2021

Primary completion

Feb 15, 2022

Study completion Feb 7, 2023

Sponsor

Lead sponsor
Bioverativ, a Sanofi companySanofi (SNY)
Sponsor type
Industry
First posted
Dec 17, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: \- To evaluate the effect of BIVV020 on the durability of platelet response in participants with persistent/chronic immune thrombocytopenia (ITP) Secondary Objectives: * To assess the safety and tolerability of BIVV020 * To assess the pharmacokinetics of BIVV020 * To assess the response rate of treatment with BIVV020 * To assess the time to response * To assess the effect of treatment with BIVV020 on the requirement for rescue ITP therapy * To assess the immunogenicity of BIVV020

Conditions

  • Immune Thrombocytopenia (ITP)

Interventions

  • SAR445088 (BIVV020)Drug

    Pharmaceutical form:solution for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With a Durable Platelet ResponseTime frame: From Week 3 to Week 24

Locations

9 sites in 6 countries. Site status is shown where the registry gives one.

  • Investigational Site Number :8400001

    Washington D.C., District of Columbia

  • Investigational Site Number :8400002

    Tamarac, Florida

  • Investigational Site Number :2030002

    Ostrava - Poruba, Czechia

  • Investigational Site Number :2760001

    Essen, Germany

  • Investigational Site Number :5280001

    Leiden, Netherlands

  • Investigational Site Number :7240001

    Palma de Mallorca, Spain

  • Investigational Site Number :7240003

    Seville, Spain

  • Investigational Site Number :7240002

    A Coruña, A Coruña [La Coruña], Spain

  • Investigational Site Number :8260002

    London, London, City of, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.